SRA's number for the day: 19
This article was originally published in SRA
A total of 19 pharmaceutical companies between 2009 and 2012 failed to submit one or more annual reports on deferred measures relating to paediatric investigation plans (PIPs) for authorized medicines, as required by the EU Paediatric Regulation1.
You may also be interested in...
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.